Published in J Clin Microbiol on November 12, 2008
Fusarium infection in lung transplant patients: report of 6 cases and review of the literature. Medicine (Baltimore) (2011) 0.97
Fusarium infection: report of 26 cases and review of 97 cases from the literature. Medicine (Baltimore) (2013) 0.86
Fusarium napiforme systemic infection: case report with molecular characterization and antifungal susceptibility tests. Springerplus (2014) 0.78
Health Risks Associated with Exposure to Filamentous Fungi. Int J Environ Res Public Health (2017) 0.75
Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev (1994) 3.58
Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis (2002) 2.44
Inoculum standardization for antifungal susceptibility testing of filamentous fungi pathogenic for humans. J Clin Microbiol (2001) 2.21
Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi. J Clin Microbiol (2003) 1.90
Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi. J Antimicrob Chemother (2002) 1.87
Emerging and less common fungal pathogens. Infect Dis Clin North Am (2002) 1.68
Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis (2004) 1.55
Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses (2007) 1.27
Fusarium infections of the skin. Curr Opin Infect Dis (2000) 1.23
Phylogeny and toxigenic potential is correlated in Fusarium species as revealed by partial translation elongation factor 1 alpha gene sequences. Mycol Res (2005) 1.17
Emerging fungi. Infect Dis Clin North Am (2006) 1.08
Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole. Pediatr Infect Dis J (2004) 1.07
In situ hybridization for the differentiation of Aspergillus, Fusarium, and Pseudallescheria species in tissue section. Diagn Mol Pathol (2003) 1.06
Successful treatment of disseminated Fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B. J Infect (2006) 1.02
Successful treatment of disseminated fusariosis. Bone Marrow Transplant (2003) 1.01
Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. J Clin Microbiol (2003) 1.01
Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia (2006) 0.86
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol (2005) 3.41
Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis (2005) 3.14
Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Crit Care Med (2014) 2.95
EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin Microbiol Infect (2012) 2.86
Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother (2006) 2.76
Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother (2009) 2.41
Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother (2008) 2.41
Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother (2008) 2.17
Fungal cell gigantism during mammalian infection. PLoS Pathog (2010) 2.04
Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob Agents Chemother (2005) 1.92
Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi. J Clin Microbiol (2003) 1.90
Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist. Med Mycol (2006) 1.88
Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob Agents Chemother (2010) 1.82
Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol (2006) 1.81
Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis. Clin Infect Dis (2014) 1.73
Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol (2009) 1.61
Prognostic factors in pediatric cancer patients admitted to the pediatric intensive care unit. J Pediatr Hematol Oncol (2009) 1.59
Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol (2008) 1.50
Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology. J Clin Microbiol (2012) 1.49
Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother (2007) 1.48
[Guidelines for the treatment of Invasive Candidiasis and other yeasts. Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2010 Update]. Enferm Infecc Microbiol Clin (2011) 1.46
Evaluation of Aspergillus PCR protocols for testing serum specimens. J Clin Microbiol (2011) 1.45
Assessment of early-onset chronic progressive anthracycline cardiotoxicity in children: different response patterns of right and left ventricles. Pediatr Cardiol (2013) 1.44
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). J Clin Microbiol (2006) 1.43
In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother (2003) 1.40
Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. Antimicrob Agents Chemother (2011) 1.39
Breakpoints for susceptibility testing should not divide wild-type distributions of important target species. Antimicrob Agents Chemother (2009) 1.39
Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother (2008) 1.37
Transient fungemia caused by an amphotericin B-resistant isolate of Candida haemulonii. J Clin Microbiol (2002) 1.30
Species recognition and clinical relevance of the zygomycetous genus Lichtheimia (syn. Absidia pro parte, Mycocladus). J Clin Microbiol (2010) 1.29
Cryptococcus neoformans capsular enlargement and cellular gigantism during Galleria mellonella infection. PLoS One (2011) 1.29
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. Antimicrob Agents Chemother (2009) 1.28
G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate. Antimicrob Agents Chemother (2003) 1.28
Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. Antimicrob Agents Chemother (2009) 1.23
Critical stages of extracting DNA from Aspergillus fumigatus in whole-blood specimens. J Clin Microbiol (2010) 1.20
Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob Agents Chemother (2013) 1.19
Antifungal efficacy during Candida krusei infection in non-conventional models correlates with the yeast in vitro susceptibility profile. PLoS One (2013) 1.18
Susceptibility testing and molecular classification of Paecilomyces spp. Antimicrob Agents Chemother (2008) 1.17
Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method. Antimicrob Agents Chemother (2013) 1.15
Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. Antimicrob Agents Chemother (2012) 1.13
Recurrent episodes of candidemia due to Candida glabrata with a mutation in hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin. Antimicrob Agents Chemother (2012) 1.13
In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother (2008) 1.11
In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi. J Antimicrob Chemother (2004) 1.08
Prevalence and susceptibility testing of new species of pseudallescheria and scedosporium in a collection of clinical mold isolates. Antimicrob Agents Chemother (2006) 1.06
Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review. J Antimicrob Chemother (2005) 1.06
EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole. Mycoses (2014) 1.05
Analysis of the influence of Tween concentration, inoculum size, assay medium, and reading time on susceptibility testing of Aspergillus spp. J Clin Microbiol (2005) 1.02
In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans. Antimicrob Agents Chemother (2008) 1.01
Role of Aspergillus lentulus 14-α sterol demethylase (Cyp51A) in azole drug susceptibility. Antimicrob Agents Chemother (2011) 1.00
Update on the epidemiology and diagnosis of invasive fungal infection. Int J Antimicrob Agents (2008) 0.99
Candidemia in neonatal intensive care units: Barcelona, Spain. Pediatr Infect Dis J (2006) 0.99
Molecular epidemiology and antifungal susceptibility patterns of Sporothrix schenckii isolates from a cat-transmitted epidemic of sporotrichosis in Rio de Janeiro, Brazil. Med Mycol (2008) 0.98
The interaction between Candida krusei and murine macrophages results in multiple outcomes, including intracellular survival and escape from killing. Infect Immun (2011) 0.98
Histoplasmosis and paracoccidioidomycosis in a non-endemic area: a review of cases and diagnosis. J Travel Med (2010) 0.98
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. Antimicrob Agents Chemother (2008) 0.98
Genotyping and antifungal susceptibility profile of Dipodascus capitatus isolates causing disseminated infection in seven hematological patients of a tertiary hospital. J Clin Microbiol (2004) 0.97
Treatment of vincristine-induced cranial polyneuropathy. J Pediatr Hematol Oncol (2005) 0.97
Paradoxical growth of Candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence. Antimicrob Agents Chemother (2013) 0.97
Breakthrough pulmonary Aspergillus fumigatus infection with multiple triazole resistance in a Spanish patient with chronic myeloid leukemia. Rev Iberoam Micol (2012) 0.96
Development and validation of a quantitative PCR assay for diagnosis of scedosporiosis. J Clin Microbiol (2008) 0.96
Evaluation of a chromogenic medium for detection of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae strains. Clin Lab (2014) 0.96
In vitro activity of nine antifungal agents against clinical isolates of Aspergillus calidoustus. Med Mycol (2010) 0.95
Molecular identification and susceptibility testing of Trichosporon isolates from a Brazilian hospital. Rev Iberoam Micol (2008) 0.95
The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agents in vitro. Expert Rev Anti Infect Ther (2010) 0.95
Direct analysis and identification of pathogenic Lichtheimia species by matrix-assisted laser desorption ionization-time of flight analyzer-mediated mass spectrometry. J Clin Microbiol (2011) 0.94
Identification of pathogenic rare yeast species in clinical samples: comparison between phenotypical and molecular methods. J Clin Microbiol (2010) 0.94
In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. Antimicrob Agents Chemother (2005) 0.94
Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J Antimicrob Chemother (2005) 0.94
Clinical case of endocarditis due to Trichosporon inkin and antifungal susceptibility profile of the organism. J Clin Microbiol (2004) 0.94
In vitro evaluation of combination of terbinafine with itraconazole or amphotericin B against Zygomycota. Diagn Microbiol Infect Dis (2003) 0.93
Distribution and antifungal susceptibility of Candida species causing nosocomial candiduria. Med Mycol (2011) 0.93
Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints. J Infect Dis (2012) 0.93
Daily antibiotic cost of nosocomial infections in a Turkish university hospital. BMC Infect Dis (2005) 0.92
Time of incubation for antifungal susceptibility testing of Aspergillus fumigatus: can MIC values be obtained at 24 hours? Antimicrob Agents Chemother (2007) 0.92
Molecular identification and susceptibility profile in vitro of the emerging pathogen Candida kefyr. Diagn Microbiol Infect Dis (2009) 0.92
Antifungal susceptibility profile in vitro of Sporothrix schenckii in two growth phases and by two methods: microdilution and E-test. Mycoses (2009) 0.91
Detection of fungal DNA by real-time polymerase chain reaction: evaluation of 2 methodologies in experimental pulmonary aspergillosis. Diagn Microbiol Infect Dis (2006) 0.91
Comparison of PCR protocols for detecting Histoplasma capsulatum DNA through a multicenter study. Rev Iberoam Micol (2013) 0.91
Process analysis of variables for standardization of antifungal susceptibility testing of nonfermentative yeasts. Antimicrob Agents Chemother (2011) 0.90
Antifungal susceptibility profile of human-pathogenic species of Lichtheimia. Antimicrob Agents Chemother (2010) 0.90